Terumo (OTCMKTS:TRUMY) Shares Gap Up - Time to Buy?

Key Points

• Terumo Corp. shares opened at $17.15, up from a previous close of $16.46, indicating a positive market response.
• The company reported $0.20 earnings per share, surpassing analysts' expectations of $0.17, although revenue was slightly below estimates at $1.76 billion.
• Terumo has a solid financial position with a current ratio of 2.64 and a low debt-to-equity ratio of 0.07, suggesting stability in its operations.

Terumo Corp. (OTCMKTS:TRUMY - Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $16.46, but opened at $17.15. Terumo shares last traded at $16.74, with a volume of 19,932 shares changing hands.

Terumo Trading Up 0.6%

The company has a current ratio of 2.64, a quick ratio of 1.53 and a debt-to-equity ratio of 0.07. The stock has a 50-day simple moving average of $17.43 and a two-hundred day simple moving average of $17.92. The firm has a market capitalization of $24.53 billion, a P/E ratio of 29.06 and a beta of 0.79.

Terumo (OTCMKTS:TRUMY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.17 by $0.03. The business had revenue of $1.76 billion during the quarter, compared to analyst estimates of $1.80 billion. Terumo had a return on equity of 9.19% and a net margin of 12.09%.

Terumo Company Profile

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.